---
title: "Watchman FLX Pro gains US FDA approval"
date: "2023-09-07T11:05:57.000Z"
publishedDate: "7 septembre 2023"
summary: "Boston Scientific has received US Food and Drug Administration (FDA) approval for the latest-generation Watchman FLX Pro left atrial appendage closure (LAAC) device. The device, which is indicated to reduce stroke risk in patients with non-valvular atrial fibrillation (NVAF) who need an alternative to oral anticoagulation therapy, now features a polymer coating, visualisation markers and [&#8230;] The post Watchman FLX Pro gains US FDA approval appeared first on Cardiovascular News ."
importance: ""
sourceUrl: "https://cardiovascularnews.com/watchman-flx-pro-gains-us-fda-approval/"
tags: ["France", "Actualité", "Cardiovascular News — Latest"]
permalink: "/papers/2023-09-07-watchman-flx-pro-gains-us-fda-approval"
imageUrl: "https://cardiovascularnews.com/wp-content/uploads/sites/14/2023/09/LAACDevice_1692827200930-HR.jpg"
imageCredit: "Image de l’article — droits possiblement réservés — https://cardiovascularnews.com/watchman-flx-pro-gains-us-fda-approval/"
---

![Watchman FLX Pro gains US FDA approval](https://cardiovascularnews.com/wp-content/uploads/sites/14/2023/09/LAACDevice_1692827200930-HR.jpg)

*Crédit image : Image de l’article — droits possiblement réservés — https://cardiovascularnews.com/watchman-flx-pro-gains-us-fda-approval/*

## L’essentiel

Boston Scientific has received US Food and Drug Administration (FDA) approval for the latest-generation Watchman FLX Pro left atrial appendage closure (LAAC) device. The device, which is indicated to reduce stroke risk in patients with non-valvular atrial fibrillation (NVAF) who need an alternative to oral anticoagulation therapy, now features a polymer coating, visualisation markers and [&#8230;] The post Watchman FLX Pro gains US FDA approval appeared first on Cardiovascular News .

## Lien source

https://cardiovascularnews.com/watchman-flx-pro-gains-us-fda-approval/
